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ABSTRACT:
Currently, advances in the area of photodynamic therapy (PDT) using porphyrin
molecules are being made and not only in this arena, but in science and society overall,
nanoparticles are of high interest. For perspective on the size of nanoscale products (such
as porphyrins or quantum dots) present in society today, consider that 2 g of 100 rundiameter nanoparticles contains enough material to provide every human worldwide with
300,000 particles each (Hardman 2006). Porphyrins are better suited for PDT than their
organic dye predecessors due to their fluorescence intensity and longevity. Currently,
Photofrin® and Visudyne®, both porphyrin-type derivatives are used in PDT. However,
the fluorescence and longevity advantages could possibly be further improved by the
successful coupling of the porphyrin molecule to nanoparticles known as quantum dots
(QDs). QDs, types of phosphors, are miniscule crystals of semiconductor material such as
zinc sulfide, cadmium sulfide, cadmium telluride, or cadmium selenide, with their overall
structure being composed of a core surrounded by an outer shell. The nature of QDs may
be altered upon modification of or additions to this outer shell - including the attachment
of porphyrin molecules (Zenkevich 2006). The resulting QD-porphYJin complex is
expected to have increased photo-efficiency and more selective biological cell imaging.
Porphyrins are known to be tumor specific and therefore the QD-porphyrin complex
should be as well.
Continuing research may include the addition of zinc to the porphyrin complex
followed by attempted coupling with QDs. A second area of further research will include
the addition ofhexadiamine through the aide of a BOC protecting group followed by
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attempted coupling with QDs, as well as investigations concerning the cellular uptake of
many of these QD-porphyrin compounds.
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INTRODUCTION:
Protocols and methods for compounds to be used in cellular imaging and
photodynamic therapy are areas of medicine in which advances are continually being
made. Not simply in these procedures, but in any facet of medical use, compounds that
are developed in a laboratory setting must be correctly characterized along with
determining that they are soluble in water. If a compound is water-soluble, then the newly
developed compound can be further analyzed for use in vivo - for example, the human
body.
In most cases concerning abnormal cell growth, the most effective route for

obtaining a correct diagnosis as well as issuing an accurate prognosis, is for physicians to
consult images of the abnormal cell growth occurring within a patient' s body. Currently,
successful cellular images are being obtained through the use of organic dyes. The
drawback to utilizing organic dyes is that they only provide an adequate amount of
fluorescence for a very limited amount of time while in the body. One option that is being
researched and developed to improve the quality output of cellular imaging and to
improve longevity of fluorescence is the possibility to make use of quantum dots (QDs).
Quantum dots are nanoparticles (2-1 0 nm) whose structure is comprised of a core of
semi-conductor material such as Zn or CdSe, surrounded by an outer shell (Shiohara
2004, Medintz 2005). At a size of 10 nrn, 3 million QDs would be able to fit within the
width of the average human thumb! QDs are capable of a highly effective level of
fluorescence which can be modified and tuned by making alterations to their outer shells
(Sui 2005). The goal of this project was to perform a successful alteration to the outer
shells of QDs by the addition of large molecules known as porphyrins.
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The structure of a porphyrin is based on the heterocyclic combination of four
pyrrole rings. This base compound can then be modified through variations of
substituents on its outer regions and/or the addition of a (typically) metal ion at its center.
Familiar porphyrin structures include chlorophyll a in plants which contains a magnesium
atom at its center and the heme molecule within the body that holds iron in its interior
(Figure 1). Porphyrins are ideal for medical use since their outer substituents may be
modified to ensure solubility in water, as is the case for porphyrin-based products
currently being used in photodynamic therapy and cellular imaging. Many forms of
porphyrins are also tumor specific, which makes them ideal for tumor marking and
cellular imaging in cancer research and treatment (Ferrari 2005).

Figure 1: Familiar Porphyrins
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The goal of this project is to be able to successfully couple porphyrin structures
onto the outer shells of QDs. This surface modification will serve two purposes. First, the
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highly insoluble QDs will be covered with a water-soluble porphyrin ·envelope' that can
provide a way for the QDs to be transported safely into a biological environment, as well
as resulting in a compound that exhibits excellent fluorescence and tumor specificity
which would be unmatched by the QD and porphyrin components on their own (Hoshino
2004).
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BACKGROU ND INFORMATION:
Humans have always been intrigued by the complex world contained within our
own bodies- this curiosity is continually being fu eled and answered through modem
medical techniques that provide cellular imaging of the inner regions of the human body.
These advances not only provide a clearer picture of how the body works as we ll as
supporting educational endeavors, but it also provides doctors and scientists with the
means to visualize internal inconsistencies that may occur withi n a patient' s body. To
obtain internal cellular images, a variety of compounds and methods such as organic
dyes, ultrasounds, and MRis, have been previously used and are currently being
improved upon in order to make the process o f procuring such images easier, fas ter, and
safer.
One such method that is c urrently being used in medicine is photodynamic
therapy (PDT) which makes use o f porphyrin-based compounds in labeling tumors so
that they can be more accurately located and destroyed (S alata 2004) . The porphyrinbased photosensitizer is inj ected into the patient and allowed to concentrate in abnormal
cells over time. Those labeled cell s can then be exposed to a certain wavelength of li ght
to acti vate the photosensitizer and in tum, destroy the tumor (Figure 2).

Figure 2: Photodynamic Therapy
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Two photosensitizers that are currently on the market are Photofrin® and Visudyne®.
Both of these products exhibit levels of fluorescence characteristic of porphyrins and aid
physicians in targeting abnormal cells associated with lung and esophageal cancers and in
treating we macular degeneration, respectively. Photofrin® is injected into the patient and
remains inactive until exposed to a laser beam of particular wavelength. Before becoming
activated by the laser, the compound is allowed time to concentrate in the tissues - it is
particularly fond of high-grade dysplasia and cancer cells which are destroyed when
Photofrin® is activated (Axcan Pharma Inc.). Visudyne® can also be injected into a
patient via the bloodstream which transports the compound to the blood vessels (involved
in sight) affected by wet macular degeneration that are located on the backside of the eye
that affect the person's ability to see. Then a laser is shone into the affected area,
Visudyne® is activated, and the vessels are sealed shut (Novartis). Both of these PDT
treatments are relatively harmless and are sufficiently capable of relieving the patient of
symptoms associated with their respective disease. Although porphyrins, as well as
traditional organic dyes, provide a way of targeting and destroying abnormal cells within
the body, their efficiency and longevity are only moderately impressive. As noticed with
these two products, PDT is effective in areas of the body that can be easily exposed to
light activation directly or by way of a scope. More defined cellular imaging and tumor
labeling may be achieved through further modification of the porphyrin-based
complexes, or by the use of a different compound entirely.
One such compound that is ofhigh interest to scientists and physicians alike is the
quantum dot (QD). A quantum dot is a nano-sized particle consisting of a core made of
semiconductor material such as Cd/Se and an outer shell. QDs exhibit excellent
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flu orescence capabilities, makin g them potential candidates for intracellular imaging and
tumor marking- however, these dot structures are not water soluble, making them less
than ideal for treatments and procedures that occur within the body (Palaniappan 2005).
By comparing the two, QDs prove to be much more e fficient in maintaining flu orescence
than their organic dye predecessors (Sungjee 2003).
Figure 3: Longevity of Fluorescence Comparison
Top Row - Organic Dye
Bottom Row - Quantum Dots
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As seen in this comparison of illuminated frog embryos, the QDs (row b) display a highl y
effecti ve level of flu orescence over time as compared to the organic dye (row a) which
gradually diss ipates (Figure 3).
Fluorescence- Fluorescence occurs when exposure to a particular wavelength of
light excites a compound 's electrons. As an exc ited electron jumps to a higher energy
level kn own as the excited state, the compound is said to exhibit absorbance of the light.
The electron then e mits visible color known as fluorescence as it fall s back to its original
ground state (Figure 4). This cyc le of absorption and flu orescence happens only while the
compound is exposed to the particular exc itation wavelength and stimulati on is induced.
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Figure 4: Fluorescence
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Phosphorescence, on the other hand, is when the excitation of a compound's electrons is
essentially stored over time and its illumination occurs whether or not the original
stimulation is continued. The principle of phosphorescence is seen in glow-in-the-dark
objects which show continual illumination that is more particularly visible to the naked
eye in the absence of light. Fluorescence is a phenomenon which is seen in both
porphyrin structures and QDs, both of which encompass the possibility of enduring
modifications that may allow for the fine-tuning of the fluorescence of either compound.
The fluorescence of many compounds can be detected , measured and verified
using an instrument known as a fluorescence spectrophotometer (Figure 5). A cuvette
containing a solution of the compound of interest is placed in the instrument, which can
be specifically programmed to expose the solution to a specified excitation wavelength.
The instrument can then read the level of fluorescence of the solution and provides a
printout with a corresponding peak displayed at the level of fluorescence.
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Figure 5: Fl uorescence Spectrophotomer
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Quantum dots may exhibit varying colors of flu orescence depending on their size
and composition (Figure 6). As the size of a QD is increased, its exhibited fluorescence
changes from blue to red in color. The QDs used in this particular proj ect were classified
as 620 nm - the wavelength at which the dots would be expected to display optimal
flu orescence for their size. As seen in Table 1, 620 nm is located at the di vision between
orange and red flu orescence and upon excitation the vial of QDs did in fact exhibit an
almost neon-orange glow. Conversely, smaller dots (and therefore those at higher energy)
show colors in the blue-green family.
Table 1: Wavelength s & Colors

Figure 6: QD Fluorescence
Image Courtesy of Prof Weller

Color

Wavelength (nm)

violet

380-450

blue

450-495

green

495-570

~dlow

570-590

orange

590-620

red

62Q-750

htto: l/www.chemie.unihamburq. de/od weller/

As previously mentioned, despite the excellent efficiency of QDs for cellular imaging
(Figure 7), the QD nanoparticles are not water soluble and are therefore less than ideal for
use within a biological system such as the human body. Current use of QDs within the
body is closely regulated with use of the nanoparticles being limited to areas of the body
where they can be removed or ex pelled quickly, avoiding potential harm to the patient .
Figure 7: Intestinal Images Usi ng QDs

Images Courtesy of The National Center for Mi croscopy and Imaging Research

Recent research concerni ng QDs has typically been foc used on their structure- most
specifically, modifications and alterations to the outer shell incl uding the addition of
bi omolecules as seen in Figure 8.
Figure 8: QD Mod ification
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Through such alterations of the outer shell, the solubility and reactivity of QDs may be
changed and more specifically tuned for medicinal use (Sui 2005). C hange in the
composition of the QD's outer shell is the main foc us of the majority of research projects,
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papers, and articles within modern scientific magazines and meetings, as well as this
thesis.
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METHODS:
Synthesis of the Porphyrin, H 2TPPC- To begin, a porphyrin structure was
synthesized and thoroughly purified. Pyrrole, 1.5 mL, was combined with 3.0 g of 4carboxybenzaldehyde (also known as 4-formylbenzoic acid) in approximately 250 mL of
propionic acid in a round bottom flask, and refluxed for 3 hours (Reaction 1). The flask
was then removed, allowed to cool to room temperature, and placed in a freezer
overnight. Observed color changes happened as the mixture refluxed with changes
ranging from a white, cloudy appearance to a dark red, finishing with a seemingly black
color. Upon removal from the freezer, the solid product was filtered and washed with
dichloromethane on a course frit and allowed to stand and thoroughly dry. Next, the dried
product was weighed and dissolved into solution with methanol. Purification of this
solution continued through the use of a rotovap machine to evaporate the methanol under
reduced pressure, followed by column chromatography. The purified product from the
rotovap was dissolved back into solution using methanol and run through a pressurized
column containing Sephadex LH-20. Each varying fraction that was expelled from the
column was collected in 50 mL flasks with the light colored fractions from the very
beginning and very end of the purification being discarded as well as a few dark green
solutions from the beginning of the column. The fractions that appeared pink in color
were retained from the column and were obtained as the final porphyrin product
following one final rotovap purification.
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Reaction I : Synthesis ofH 2TPPC

HOOC
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H
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acid

COOH
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COOH

Synthesis of H 2TPPEA began by combining H 2TPPC, 0.25 g, 0.313 g of 1Hydroxy-benzotriazole hydrate (HOBT), 0.205 g of of 1,3-dicyclohexylcarbodiimide
(DCC), and 0.160 g diethanolamine in approximately 50 mL oftetrahydrofuran (THF)
and stirred for 1 hour in a round bottom flask. Then the reaction was modified by the
addition of2 mL of water, THF was decanted off, and then the flask was all owed to sit
overnight to facilitate complete evaporation of the THF that remained. The resulting
product was then dissolved in 50/50 methanol/H 20 and purified by co lumn
chromatography using Sephadex LH-20. The red portion ofthe solution that eluted from
the column was then collected and rotovapped. This purification was repeated using
Sephadex LH-20 utilizing H 20 as the eluent. The pink porphyrin fraction was collected
and evaporated under reduced pressure to yield the purified H2TPPEA (Reaction 2).
Sephadex LH-20 is a chromatography material that separates a solution based on its
lipophilicity, whil e Sephadex G-50 focuses on separation as a direct result of size. By
performing preliminary reactions, the need for the inclusion of water to the synthesis of
H2TPPEA was found to be unnecessary. In the end, coupling with QDs occurred using
not H2TPPEA, but H 2TPPC.

Reaction 2: Synthesis ofH 2TPPEA

HOOC

Synthesis of Quantum Dots - Although no QDs were directly synthesized for this
project, the synthesis of most variations of QDs happens by way of a two-step process.
Prolysis of organometallic precursors (such as dimethyl cadmium and trioctylphosphine
selenide) was conducted in trioctylphosphine oxide (TOPO). The precursors were
injected into a flask at temperatures within the range of 340 to 360 oc followed by the
addition ofTOP, which generated small dots grown between 290 and 300 °C that were
later collected as powders using size-selective precipitation with methanol and completed
by redispersion in hexane. The resulting product constitutes the Cd/Se cores of many
QDs. The second step served to generate a shell around the initial core. For example, a
Zn/S shell was synthesized by using the precursors diethylzinc and
hexamethyldisilathiane. Equimolar amounts of the precursors were dissolved in TOP
inside an inert atmostphere glovebox, which were then transferred to a funnel onto the
top of the reaction flask that already contained the Cd/Se cores under a heated
atmosphere ofN 2. The precursors were carefully injected at specific temperatures
according to the desired final dot size. This two-fold process of core and shell creation is
the general process for the synthesis of most QDs (Medintz 2005).

16

Synthesis of QD-Porphyrin Complex - To attempt the conjugation of porphyrins
with QDs, a primary protocol from Invitrogen (2005) was studied and modified. Trials
without quantum dots, containing only diethanolamine, DCC, HOBT, and porphyrin,
were performed to determine the amounts of each reactant that would be sufficient for the
detection and viewing of a final product on UV -vis and the fluorescence
spectrophotometer, and to assess which technique for the reaction set-up/environment
was best.
The best experimental set-up for coupling the QDs with the porphyrin structures
was determined strictly through trial and error - although the previous reactions using
diethanolamine were conducted in fairly small amounts, the reactions with QDs would
have to be on a nano scale. As a result, the same weights of DCC, HOBT, and H2TPPC
were used, with those amounts being dissolved and diluted in volumetric flasks using
methanol, from which microliter amounts of each were used. The initial reaction
equipment set-up included a microscale flask and small stir bar. This, however, proved to
be too large for the microliter amounts of reactants being used and a 1 mL centrifuge tube
held to a vortex mixer by a ring stand (to ensure constant shaking) was decided upon.
The first round of dilutions and reactions proceeded as follows:
H2TPPC, 0.25 g, was dissolved in a 100 mL volumetric flask, 0.313 g DCC in a
10 mL volumetric flask, 0.205 g HOBT in a 5 mL volumetric flask, and 0.160 g of
diethanolamine in a 5 mL volumetric flask. Then, I mL of the H2TPPC was diluted from
the first flask to a second 100 mL volumetric flask. These dilutions were then followed
by an initial trial reaction (with no QDs), which consisted of250

~L

of diethanolamine

and 10 ~L of DCC, HOBT, and H2TPPC each. This mixture was stirred in a microscale
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flask for 2 hours and then purification was accomplished by running the product through
column made of a 1 mL syringe containing Sephadex LH-20 and utilizing 50/50
methanol/H 2 0 as the eluent. The initial drops to elute from the column were assumed to
be unreacted DCC and HOBT and were discarded. The following collected fraction was
then diluted using methanol and analyzed using UV -vis spectroscopy. This first trial
reaction was successful in that a UV-vis absorbance maximum was observed at 415 nm,
which is indicative of the presence of porphyrin in the solution (the porphyrin so ret band
is located at 415 nm). From this information, it was determined that dilutions of the
original weights of reactants and the microliter amounts used were indeed appropriate for
the reaction to be detected by UV-vis spectroscopy and fluorescence spectroscopy A few
more practice reactions were completed with less than adequate results, but a final
determination of reactant amounts and apparatus set-up was eventually reached.
Due to the limited volume ofQDs available for use, UV-vis techniques were used
to once again determine approximate concentrations that would be appropriate for
achieving a successfully coupled product that could be characterized using the
fluorescence spectrophotometer. The previously mentioned solution that displayed the
characteristic porphyrin peak at 415 nm was used as a reference in concentration and
color to approximate the necessary amounts of not only QDs, but the more dilute version
of the porphryin to be used in the coupling reactions (Table 2).
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Table 2: Trials to Compare Color of Reference
Trial #

Porphyrin

(~L)

Methanol

1

10

990

2

5

995

3

7.5

992.5

4

12

988

5

20

980

6

15

985

(~L)

After running 6 trials, trial number 1 was selected as being the closest in color and
concentration to the earlier solution and it was easily detected by UV -vis spectroscopy.
This process helped to determine that 10

~L

would be an appropriate amount to use in the

coupling reactions for both the porphyrin compound and QDs.
Following trial reactions void of QDs, UV -vis techniques were used to determine
the approximate concentrations of QDs and porphyrin that were used. UV -vis analysis
also led to the determination that the more concentrated porphyrin from the original 5 mL
volumetric dilution (versus a dilute version in a 100 mL volumetric flask) worked best in
trial reactions using QDs. Successful coupling was immediately achieved using the
fo llowing components:
Ten

~Leach

of QDs and concentrated porphyrin as well as 50 ~L of diluted DCC

and HOBT were added to a centrifuge bullet, wrapped in aluminum foil , clamped on a
ring stand, and shaken on a vortex m ixer for 2 hours. When using the QDs, care was
taken to handle them with minimal light exposure while wearing protective gloves at all
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times. After being shaken for 2 hours, the solution was purified through microscale
column chromatography using Sephadex G-50 and methanol as the eluting solvent. As
before, the first drops to elute from the column were assumed to be unreacted DCC and
HOBT and were discarded, and the final product was collected for characterization.
Characterization of the QD-porphyrin Complex - To accurately determine
whether or not successful coupling of the porphyrin structure(s) with QDs occurred the
collected reaction product was analyzed using a Hitachi F-2000 fluorescence
spectrophotometer. The reaction mixture was transferred from the small glass HPLC vial
in which it was collected from column chromatography, to a plastic cuvette followed by
the addition of methanol to dilute the solution to the appropriate level to be analyzed by
the spectrofluorimeter (approximately 2/3 of the 1 mL cuvette). The QDs being used
were labeled as 620 nrn Cd/Se quantum dots, so Ocean NanoTech LLC was consulted to
determine which excitation wavelength would exhibit the desired fluorescence at 620 nrn.
The company verified that in order to obtain the desired optimal fluorescence of those
particular dots at 620 nrn, the excitation wavelength would need to be set at 500 nrn.
Various solutions were run using the fluorescence spectrophotometer, including a
methanol blank, 10 11L of QDs in methanol, I 0 11L of porphyrin in methanol, and finally
the reaction product. The first three solutions were analyzed in order to obtain
reference/standard peaks at 500 nrn, 620 nm, and 650 nm respectively. Data for four of
the solutions ' emission spectra were obtained and viewed , with appropriate rescaling of
they-axis incorporated in the analysis if necessary.
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RESULTS :
Before attempting a coupling reaction, UV-vis techniq ues were used to veri fy that
the porphyrin complex had in fact been synthes ized and to determine appropriate
amounts of reactants to be used to ensure detec tion by the flu orescence
spectrophotometer. The porphyrin did display the characteristic soret band at 4 15 nm,
validating the assumption that H 2TPPC had been successfully synthesized and ensuring
that the methods for generating both H2TPPC and H2TPPEA were correct (Figure 9).
Figure 9: UV-v is Spectrum of H 2TPPC
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Reactions were then used to attempt coupling of porphyrin structures with the Q Ds, with
the reaction product being analyzed by a flu orescence spectrophotometer. First, the
separate reaction components were analyzed using the instrument, including methanol, 10

ML o f H2TPPEA in methanol, and 10 ML QDs in methanol. The fo llowing emi ssion
spectra were obtained .
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Figure l 0: Emission Spectra
10 A: Methanol only- peak at 500 nm
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10 B: Quantum Dots in Methanol- peak at 620 nm
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10 D: Successful Reaction- Porphyrin peak at 650 nm with QD shoulder at 620 nm
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As expected, the coupled complex exhibited a strong peak at 650 nm and a shoulder at
620 nm, indicative of the presence of a conjoined product of porphyrin and QDs
respective! y.

23

CONCLUSIONS:
Basic conclusions as a result of this project include the following:

1. H 2TPPC was successfully synthesized and characterized using UV -vis spectroscopy.
2. H 2TPPEA was successfully synthesized and characterized using UV -vis spectroscopy.
3. A protocol was developed for coupling QDs with porphyrins.
4. H 2TPPC was successfully coupled to QDs as determined by fluorescence
spectroscopy.
Future research may consist of synthesis, purification and characterization of a
metallated porphyrin complex, which would then be coupled with QDs - more
specifically, the addition ofZn to the porphyrin complex followed by attempted coupling
with QDs and the addition of hexadiamine through the aide of a BOC group followed by
attempted coupling with QDs. Cells could then be treated with the coupled complex,
exposed to light and resulting changes in their growth and potential fluorescence could be
monitored and analyzed. The outlook for this area of research appears hopeful as more
specific coupling protocols are developed, continued variations in the structure and
components of both porphyrins and QDs are synthesized and used, and methods for
further tuning of fluorescence and tumor specificity are achieved. Overall, as porphyrinbased compounds can become more water soluble, then they are in tum more appropriate
for use in medical treatments and procedures. The possibility that these successfully safe
compounds can someday be used in conjunction with highly efficient quantum dots will
continue to serve as a catalyst in generating interest in the coupling of the two
components for use in medical treatments that seek to improve the well being of patients.
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